Charles River Laboratories International, Inc. (NYSE:CRL) VP Birgit Girshick sold 1,675 shares of the firm’s stock in a transaction dated Friday, February 19th. The shares were sold at an average price of $293.92, for a total transaction of $492,316.00. Following the completion of the sale, the vice president now owns 31,680 shares of the company’s stock, valued at approximately $9,311,385.60. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Charles River Laboratories International stock traded down $3.15 during trading on Tuesday, reaching $280.44. The company’s stock had a trading volume of 5,553 shares, compared to its average volume of 342,970. The business’s 50-day moving average price is $274.86 and its 200-day moving average price is $241.52. The firm has a market cap of $13.96 billion, a PE ratio of 47.27, a P/E/G ratio of 2.19 and a beta of 1.12. Charles River Laboratories International, Inc. has a 52 week low of $95.58 and a 52 week high of $303.79. The company has a quick ratio of 1.22, a current ratio of 1.45 and a debt-to-equity ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Tuesday, February 16th. The medical research company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.28. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. Equities analysts predict that Charles River Laboratories International, Inc. will post 7.87 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Altshuler Shaham Ltd bought a new stake in Charles River Laboratories International during the third quarter worth about $28,000. Jeppson Wealth Management LLC bought a new stake in Charles River Laboratories International during the third quarter worth about $29,000. Trust Co. of Vermont bought a new stake in Charles River Laboratories International during the third quarter worth about $31,000. Berman Capital Advisors LLC lifted its position in Charles River Laboratories International by 42.6% during the fourth quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock worth $34,000 after purchasing an additional 43 shares during the period. Finally, Archer Investment Corp bought a new stake in Charles River Laboratories International during the fourth quarter worth about $38,000. 92.30% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have weighed in on CRL shares. Truist raised their price objective on shares of Charles River Laboratories International from $256.00 to $324.00 in a research report on Thursday, February 18th. Smith Barney Citigroup lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 16th. Credit Suisse Group lifted their price objective on shares of Charles River Laboratories International from $259.00 to $301.00 and gave the company a “neutral” rating in a report on Thursday, February 18th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $270.00 to $250.00 in a report on Wednesday, December 16th. Finally, Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, February 18th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Charles River Laboratories International has a consensus rating of “Buy” and a consensus target price of $237.41.

About Charles River Laboratories International

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Trading on Margin

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.